CA3068363A1 - Identification and elimination of damaged and/or senescent cells - Google Patents
Identification and elimination of damaged and/or senescent cells Download PDFInfo
- Publication number
- CA3068363A1 CA3068363A1 CA3068363A CA3068363A CA3068363A1 CA 3068363 A1 CA3068363 A1 CA 3068363A1 CA 3068363 A CA3068363 A CA 3068363A CA 3068363 A CA3068363 A CA 3068363A CA 3068363 A1 CA3068363 A1 CA 3068363A1
- Authority
- CA
- Canada
- Prior art keywords
- damaged
- cells
- antagonist
- senescent cells
- interaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382417.8A EP3421607A1 (en) | 2017-06-29 | 2017-06-29 | Identification and elimination of damaged and/or senescent cells |
| EP17382417.8 | 2017-06-29 | ||
| PCT/EP2018/067655 WO2019002581A1 (en) | 2017-06-29 | 2018-06-29 | IDENTIFICATION AND ELIMINATION OF DAMAGED AND / OR SENESCENT CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3068363A1 true CA3068363A1 (en) | 2019-01-03 |
Family
ID=59315550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3068363A Pending CA3068363A1 (en) | 2017-06-29 | 2018-06-29 | Identification and elimination of damaged and/or senescent cells |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200123607A1 (https=) |
| EP (2) | EP3421607A1 (https=) |
| JP (2) | JP2020525021A (https=) |
| CA (1) | CA3068363A1 (https=) |
| WO (1) | WO2019002581A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11401324B2 (en) | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| US11518792B2 (en) | 2018-08-30 | 2022-12-06 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CN120924491A (zh) | 2019-06-21 | 2025-11-11 | 免疫生物公司 | 多链嵌合多肽和其用途 |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| WO2021163299A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Chromatography resin and uses thereof |
| CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
| US12024545B2 (en) * | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US20250108036A1 (en) * | 2021-11-10 | 2025-04-03 | Lifeceutix Co., Ltd. | Compositions for removing senescent cells and uses thereof |
| CN114836508A (zh) * | 2021-12-08 | 2022-08-02 | 上海锐翌医学检验实验室有限公司 | 慢性阻塞性肺病标志微生物及其应用 |
| EP4486457A1 (en) | 2022-03-04 | 2025-01-08 | Rejuveron Senescence Therapeutics AG | Anti pd-l2 antibody |
| WO2023201311A1 (en) | 2022-04-13 | 2023-10-19 | HCW Biologics, Inc. | Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder |
| JPWO2023238845A1 (https=) * | 2022-06-07 | 2023-12-14 | ||
| CN115154611B (zh) * | 2022-06-23 | 2023-11-17 | 中山大学孙逸仙纪念医院 | 免疫检查点抑制剂与抗衰老药物联合在制备肿瘤治疗产品中的用途 |
| WO2024063109A1 (ja) * | 2022-09-20 | 2024-03-28 | 国立大学法人東京大学 | 老化細胞除去剤 |
| KR20260008114A (ko) * | 2023-05-04 | 2026-01-15 | (주)라이프신약 | 노화세포 제거 또는 억제용 조성물 및 이의 용도 |
| WO2024249938A1 (en) * | 2023-05-31 | 2024-12-05 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating senescence/age-related diseases |
| WO2025051889A1 (en) * | 2023-09-06 | 2025-03-13 | Rejuveron Senescence Therapeutics Ag | Anti pd-l2 antibodies for use in treating fibrotic diseases |
| CN120960439A (zh) * | 2025-10-14 | 2025-11-18 | 中南大学湘雅医院 | Usp51的抑制剂与pd-l1/pd-1单抗药物联用在制备肿瘤免疫治疗药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JP2004501631A (ja) * | 2000-06-28 | 2004-01-22 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用 |
| AU2005248958A1 (en) * | 2000-06-28 | 2006-02-02 | Brigham And Women's Hospital | PD-L2 molecules: novel PD-1 ligands and uses therefor |
| US20170037125A1 (en) * | 2014-02-04 | 2017-02-09 | Incyte Corporation | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| WO2016134416A1 (en) * | 2015-02-23 | 2016-09-01 | The University Of Queensland | A method for assessing prognosis of lymphoma |
| US20160362489A1 (en) * | 2015-04-28 | 2016-12-15 | Bristol-Myers Squibb Company | Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody |
| KR20180015269A (ko) * | 2015-06-24 | 2018-02-12 | 이모듈런 테라퓨틱스 리미티드 | 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포 |
| CA2995502A1 (en) * | 2015-09-21 | 2017-03-30 | Merck Sharp & Dohme Corp. | Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof |
-
2017
- 2017-06-29 EP EP17382417.8A patent/EP3421607A1/en not_active Withdrawn
-
2018
- 2018-06-29 US US16/627,034 patent/US20200123607A1/en not_active Abandoned
- 2018-06-29 CA CA3068363A patent/CA3068363A1/en active Pending
- 2018-06-29 JP JP2019572038A patent/JP2020525021A/ja active Pending
- 2018-06-29 EP EP18735568.0A patent/EP3645746A1/en not_active Withdrawn
- 2018-06-29 WO PCT/EP2018/067655 patent/WO2019002581A1/en not_active Ceased
-
2023
- 2023-04-05 JP JP2023061595A patent/JP2023098947A/ja active Pending
-
2024
- 2024-06-21 US US18/750,834 patent/US20240344128A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023098947A (ja) | 2023-07-11 |
| WO2019002581A1 (en) | 2019-01-03 |
| US20200123607A1 (en) | 2020-04-23 |
| US20240344128A1 (en) | 2024-10-17 |
| EP3421607A1 (en) | 2019-01-02 |
| EP3645746A1 (en) | 2020-05-06 |
| JP2020525021A (ja) | 2020-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240344128A1 (en) | Identification and elimination of damaged and/or senescent cells | |
| US20250199005A1 (en) | Depleting tumor-specific tregs | |
| EP4129336B1 (en) | Anti-cd47 agent-based treatment of cd20-positive cancer | |
| JP6564408B2 (ja) | Ｓ１００ａ４抗体およびその治療上の使用 | |
| US20200155675A1 (en) | Methods and compositions for cancer treatment and treatment selection | |
| JP2020517640A (ja) | 併用療法 | |
| HK1252272A1 (zh) | 使用抗ox40抗体治疗癌症的方法 | |
| JP7402691B2 (ja) | 抗ｃｄ２５抗体薬物複合体による併用療法 | |
| KR20140024914A (ko) | 예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법 | |
| IL278854B1 (en) | Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopypyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile | |
| JP6316498B2 (ja) | Ｃｋａｐ４を標的分子とした抗腫瘍剤 | |
| US12173042B2 (en) | Methods of treating cancers with CT45 targeted therapies | |
| JP2020517629A5 (https=) | ||
| WO2020071554A1 (ja) | がん幹細胞特異的抗体 | |
| EP4215211A1 (en) | Tumor immune microenvironment regulator, and preventive, diagnostic or therapeutic use thereof | |
| WO2008046529A1 (en) | Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule | |
| WO2008046459A1 (en) | Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule | |
| JP7853352B2 (ja) | 多発性骨髄腫を治療すること及び４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルのバイオマーカーの使用 | |
| AU2024351102A1 (en) | Treatment of cancers associated with beta-catenin | |
| TW202528342A (zh) | Ｈｌａ／癌症抗原ｐｖｔ１衍生胜肽複合體特異性抗體 | |
| NZ750663A (en) | Compositions and methods for cancer immunotherapy | |
| HK40043124B (en) | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies | |
| HK40043124A (en) | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies | |
| EA041126B1 (ru) | Антитела и полипептиды, направленные против cd127 | |
| NZ750663B2 (en) | Compositions and methods for cancer immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220308 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240814 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20241120 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250415 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250603 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250603 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250620 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250620 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250710 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250804 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250908 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250908 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251110 |